Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The extent to which individual statins vary in terms of clinical outcomes across all populations, in addition to secondary and primary prevention has not been studied extensively in meta-analyses. METHODS: We systematically studied 199,721 participants in 92 placebo-controlled and active-comparator trials comparing atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin in participants with, or at risk of developing, cardiovascular disease. We performed pairwise and network meta-analyses for major coronary events and all-cause mortality outcomes, taking into account the dose differences across trials. Systematic review registration: PROSPERO 2011:CRD42011001470. RESULTS: There were only a few trials that evaluated fluvastatin. Most frequent comparisons occurred between pravastatin and placebo, atorvastatin and placebo, and rosuvastatin and atorvastatin. No trial directly compared all six statins to each other. Across all populations, statins were significantly more effective than control in reducing all-cause mortality (OR 0.87, 95% credible interval 0.82-0.92) and major coronary events (OR 0.69, 95% CI 0.64-0.75). In terms of reducing major coronary events, atorvastatin (OR 0.66, 95% CI 0.48-0.94) and fluvastatin (OR 0.59, 95% CI 0.36-0.95) were significantly more effective than rosuvastatin at comparable doses. In participants with cardiovascular disease, statins significantly reduced deaths (OR 0.82, 95% CI 0.75-0.90) and major coronary events (OR 0.69, 95% CI 0.62-0.77). Atorvastatin was significantly more effective than pravastatin (OR 0.65, 95% CI 0.43-0.99) and simvastatin (OR 0.68, 95% CI 0.38-0.98) for secondary prevention of major coronary events. In primary prevention, statins significantly reduced deaths (OR 0.91, 95% CI 0.83-0.99) and major coronary events (OR 0.69, 95% CI 0.61-0.79) with no differences among individual statins. Across all populations, atorvastatin (80%), fluvastatin (79%), and simvastatin (62%) had the highest overall probability of being the best treatment in terms of both outcomes. Higher doses of atorvastatin and fluvastatin had the highest number of significant differences in preventing major coronary events compared with other statins. No significant heterogeneity or inconsistency was detected. CONCLUSIONS: Statins significantly reduce the incidence of all-cause mortality and major coronary events as compared to control in both secondary and primary prevention. This analysis provides evidence for potential differences between individual statins, which are not fully explained by their low-density lipoprotein cholesterol-reducing effects. The observed differences between statins should be investigated in future prospective studies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Statins usually reduce TG levels by 10-20% from baseline values [199].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [199]
In the citing paper
“More potent statins (atorvastatin, rosuvastatin, and pitavastatin) demonstrate robust lowering of TG levels, especially at high doses and in patients with elevated TGs (HTG), in whom the absolute risk, and therefore the absolute risk reduction, is larger.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [199]
Citations
Cites
A basic introduction to fixed-effect and random-effects models for meta-analysis
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2010) · Research Synthesis Methods · doi:10.1002/jrsm.12 · Cited by 6,793 · cited 1×
“First, we performed classical pairwise meta-analyses to synthesize studies that compared the same two treatments using the Mantel–Haenszel (fixedeffect) and Der Simonian Laird (random-effects) method.(26) Forest plots of the relative treatment effects from the individual trials and pairwise meta-analyses were visually…”
MethodCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Salanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766 · cited 1×
“We developed rankograms and cumulative probability plots to graphically present the distribution of ranking probabilities and estimated the surface under the cumulative ranking (SUCRA) line for each statin.(30) To estimate inconsistency between direct and indirect evidence, we calculated the ratio of relative effects…”
MethodSelf-citationHigh-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887
Combination of direct and indirect evidence in mixed treatment comparisons
Lu, G., & Ades, A. E. (2004) · Statistics in Medicine · doi:10.1002/sim.1875 · Cited by 2,166 · cited 1×
“Study-level relative treatment effects were combined using random-effects models using Bayesian Markov chain Monte Carlo methods.(29) We considered the findings significant when the 95% credible intervals (CI) for odds ratios (OR) did not include the null value 1.”
MethodSelf-citationCollaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081 · cited 1×
“Prior metaanalyses have demonstrated the effectiveness of statins in secondary prevention, among the elderly,(11,12) and in individuals with diabetes.(13,14) Initially focused on secondary prevention, statin therapy has become more common as the limits of treatment have expanded over time to include persons at progres…”
BackgroundStatins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720 · cited 1×
“Doses considered in our base-case analysis were comparable and, as expected, resulted in approximately 30–40% reductions from baseline serum low-density lipoprotein cholesterol (LDL-C) levels.(7) Atorvastatin and fluvastatin performed significantly better than rosuvastatin in terms of reducing major coronary events ac…”
Simultaneous comparison of multiple treatments: Combining direct and indirect evidence.
Caldwell, D. M., Ades, A. E., & Higgins, J. P. T. (2005) · BMJ · doi:10.1136/bmj.331.7521.897 · Cited by 1,600 · cited 1×
“To determine the comparative effects of statins, we conducted network meta-analyses.(27) This type of analysis allowed for combining the direct within-trial comparisons between two treatments (atorvastatin vs.”
MethodSelf-citationEffect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials
LaRosa, J. C., He, J., & Vupputuri, S. (1999) · JAMA · doi:10.1001/jama.282.24.2340 · Cited by 1,246
Jansen, J. P., Fleurence, R., Devine, B., Itzler, R., Barrett, A., Hawkins, N., Lee, K., Boersma, C., Annemans, L., & Cappelleri, J. C. (2011) · Value in Health · doi:10.1016/j.jval.2011.04.002 · Cited by 1,036 · cited 1×
“control).(28) This analysis preserved the within-trial randomized treatment comparison of each trial while combining all available comparisons between treatments.”
MethodSelf-citation(1997) · New England Journal of Medicine · doi:10.1056/nejm199701163360301 · Cited by 970
Brugts, J. J., Yetgin, T., Hoeks, S. E., Gotto, A. M., Shepherd, J., Westendorp, R. G. J., de Craen, A. J. M., Knopp, R. H., Nakamura, H., Ridker, P., et al. (2009) · BMJ · doi:10.1136/bmj.b2376 · Cited by 792 · cited 1×
“With reductions estimated at 9%, our analysis confirms the all-cause mortality benefit of statin therapy observed in previous meta-analyses.(17) In contrast to most recent reviews,(18) our analysis achieved a higher precision around this estimate (with statistical significance) as a result of including trials with ver…”
ResultSelf-citationMeta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
Cannon, C. P., Steinberg, B. A., Murphy, S. A., Mega, J. L., & Braunwald, E. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.070 · Cited by 770 · cited 1×
“Our dose-specific analysis paralleled the findings of previous meta-analyses in that statins at higher doses do not reduce all-cause mortality more so than statins at lower doses.(33) Similar to previous meta-analyses, there was a general dose-response relationship across placebo-controlled and active-comparator trial…”
ResultHebert, P. R. (1997) · JAMA · doi:10.1001/jama.1997.03550040069040 · Cited by 740
Serruys, P. W. J. C. (2002) · JAMA · doi:10.1001/jama.287.24.3215 · Cited by 719
Crouse, J. R., Raichlen, J. S., Riley, W. A., Evans, G. W., Palmer, M. K., O’Leary, D. H., Grobbee, D. E., Bots, M. L., & METEOR Study Group, F. T. (2007) · JAMA · doi:10.1001/jama.297.12.1344 · Cited by 708
Blankenhorn, D. H., Azen, S. P., Kramsch, D. M., Mack, W. J., Cashin-Hemphill, L., Hodis, H. N., DeBoer, L. W. V., Mahrer, P. R., Masteller, M. J., Vailas, L. I., et al. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-10-199311150-00002 · Cited by 637
HEBERT, P. R., GAZIANO, J. M., CHAN, K. S., & HENNEKENS, C. H. (1998) · Survey of Anesthesiology · doi:10.1097/00132586-199806000-00060 · Cited by 506
Hopewell, S., Dutton, S., Yu, L.-M., Chan, A.-W., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c723 · Cited by 504 · cited 1×
“The quality of reporting remains well below an acceptable level, particularly for older trials, which complicates assessments of their conduct and validity.(47) Second, there were only a few head-to-head trials of statins that were prospectively designed to capture differences in clinical outcomes as primary endpoints.”
BackgroundRay, K. K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.182 · Cited by 446
Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments
Mills, E. J., Rachlis, B., Wu, P., Devereaux, P. J., Arora, P., & Perri, D. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.039 · Cited by 423
Statins for Secondary Prevention in Elderly Patients
Afilalo, J., Duque, G., Steele, R., Jukema, J. W., de Craen, A. J. M., & Eisenberg, M. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.06.063 · Cited by 350
Costa, J., Borges, M., David, C., & Carneiro, A. V. (2006) · BMJ · doi:10.1136/bmj.38793.468449.ae · Cited by 340 · cited 1×
“Prior metaanalyses have demonstrated the effectiveness of statins in secondary prevention, among the elderly,(11,12) and in individuals with diabetes.(13,14) Initially focused on secondary prevention, statin therapy has become more common as the limits of treatment have expanded over time to include persons at progres…”
BackgroundMills, E. J., WU, P., Chong, G., Ghement, I., Singh, S., Akl, E. A., Eyawo, O., Guyatt, G., Berwanger, O., & Briel, M. (2011) · QJM · doi:10.1093/qjmed/hcq165 · Cited by 338
Cheung, B. M. Y., Lauder, I. J., Lau, C., & Kumana, C. R. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2003.02060.x · Cited by 304
Lack of Effect of Lovastatin on Restenosis after Coronary Angioplasty
Weintraub, W. S., Boccuzzi, S. J., Klein, J. L., Kosinski, A. S., King, S. B., Ivanhoe, R., Cedarholm, J. C., Stillabower, M. E., Talley, J. D., DeMaio, S. J., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312002 · Cited by 289
Effectiveness of Statin Therapy in Adults With Coronary Heart Disease
Wilt, T. J., Bloomfield, H. E., MacDonald, R., Nelson, D., Rutks, I., Ho, M., Larsen, G., McCall, A., Pineros, S., & Sales, A. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.13.1427 · Cited by 275
Serruys, P. (1999) · European Heart Journal · doi:10.1053/euhj.1998.1150 · Cited by 259
Clinical Outcomes in Statin Treatment Trials: A Meta-analysis
Ross, S. D., Allen, I. E., Connelly, J. E., Korenblat, B. M., Smith, M. E., Bishop, D., & Luo, D. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.15.1793 · Cited by 217
The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials
Josan, K., Majumdar, S. R., & McAlister, F. A. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.070675 · Cited by 201
Song, F., Xiong, T., Parekh-Bhurke, S., Loke, Y. K., Sutton, A. J., Eastwood, A. J., Holland, R., Chen, Y.-F., Glenny, A.-M., Deeks, J. J., et al. (2011) · BMJ · doi:10.1136/bmj.d4909 · Cited by 199 · cited 1×
“We defined inconsistency as the disagreement between direct and indirect evidence with a 95% CI excluding 1.(31) To obtain a comprehensive estimate of the effect of statins in major coronary events and all-cause mortality, our network meta-analysis pooled all primary and secondary prevention trials in addition to tria…”
MethodPrevention of restenosis by lovastatin after successful coronary angioplasty
Sahni, R., Maniet, A. R., Voci, G., & Banka, V. S. (1991) · American Heart Journal · doi:10.1016/0002-8703(91)90002-y · Cited by 161
Riegger, G. A. J., Abletshauser, C., Ludwig, M. Z., SCHWANDT, P., Widimsky, J., Jr., Weidinger, G., & Welzel, D. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00062-3 · Cited by 122
Zhou, Z., Rahme, E., & Pilote, L. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.04.003 · Cited by 121 · cited 1×
“Equally importantly, these analyses did not differentiate between primary- and secondary-prevention populations.(24) Finally, previous network meta-analyses did not assess differences in dosages of individual statins across populations and did not compare statins at similar doses.”
ResultAre drugs within a class interchangeable?
Furberg, C. D., Herrington, D. M., & Psaty, B. M. (1999) · The Lancet · doi:10.1016/s0140-6736(99)03190-6 · Cited by 117 · cited 1×
“Second, whether individual statins vary in terms of their effect on clinical outcomes when compared head-to-head is unclear and has not been studied in a comprehensive manner in previous meta-analyses.(20) Information regarding the relative clinical value of different statins in primary and secondary prevention of car…”
BackgroundEfficacy and Safety of Statin Monotherapy in Older Adults: A Meta-Analysis
Roberts, C. G. P., Guallar, E., & Rodriguez, A. (2007) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/62.8.879 · Cited by 107
Stein, E. A., Strutt, K., Southworth, H., Diggle, P. J., & Miller, E. (2003) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.08.009 · Cited by 106
Leiter, L. A., Rosenson, R. S., Stein, E. A., Reckless, J. P. D., Schulte, K.-L., Schleman, M. M., Miller, P., Palmer, M. K., & Sosef, F. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.12.001 · Cited by 69
Alberton, M., Wu, P., Druyts, E., Briel, M., & Mills, E. J. (2012) · QJM: An International Journal of Medicine · doi:10.1093/qjmed/hcr158 · Cited by 66
Directed acyclic graphs can help understand bias in indirect and mixed treatment comparisons
Jansen, J. P., Schmid, C. H., & Salanti, G. (2012) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.01.002 · Cited by 65 · cited 1×
“Heterogeneity that is unexplained or unaccounted for may introduce bias only if it influences different statins to a different extent.(48) For instance, it is possible that there is an imbalance across the included set of trials in terms of baseline characteristics: trials of atorvastatin may have included patients wh…”
BackgroundStone, P. H., Lloyd-Jones, D. M., Kinlay, S., Frei, B., Carlson, W., Rubenstein, J., Andrews, T. C., Johnstone, M., Sopko, G., Cole, H., et al. (2005) · Circulation · doi:10.1161/01.cir.0000160866.90148.76 · Cited by 51
Reviews: Fluvastatin: Effects Beyond Cholesterol Lowering
Corsini, A. (2000) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840000500304 · Cited by 43
Miller, D. B. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440390031005 · Cited by 29
Statin prescription in men and women at cardiovascular risk: to whom and when?
Brugts, J. J., & Deckers, J. W. (2010) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32833cd58f · Cited by 21 · cited 1×
“Initially focused on secondary prevention, statin therapy has become more common as the limits of treatment have expanded over time to include persons at progressively lower risk of developing cardiovascular disease.(15) As the number of individuals eligible for statin therapy continues to increase both in primary and…”
BackgroundSelf-citationMaking the Case for Selective Use of Statins in the Primary Prevention Setting
Minder, C. M. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.349 · Cited by 7 · cited 2×
“First, there is no consensus around the benefit of statins in primary prevention.(16) Although previous meta-analyses have provided evidence in support of the use of statins in individuals with no evidence of cardiovascular disease,(17) recent studies challenged these findings.”
BackgroundResult
Research works printed but not linked: 1
- 10.1016/j.jacc.2006.04.070 · DOI · Paper page
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“The absolute benefit from statin treatment was lower in people in primary prevention, who are typically at lower risk.(36,38,214,215) In the CTT meta-analysis of treatment in people with a low-risk of vascular disease,(36) the relative risk reduction of major vascular events per mmol/L reduction in LDL-C was at least…”
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
“Finally, statins are described to exert beneficial effects on cardiovascular mortality and morbidity, that is especially of interest in patients with NASH [290].”
BackgroundNaci, H., & Ioannidis, J. P. A. (2013) · BMJ · doi:10.1136/bmj.f5577 · Cited by 630
Self-citationRamsden, C. E., Zamora, D., Majchrzak-Hong, S., Faurot, K. R., Broste, S. K., Frantz, R. P., Davis, J. M., Ringel, A., Suchindran, C. M., & Hibbeln, J. R. (2016) · BMJ · doi:10.1136/bmj.i1246 · Cited by 359
Metadata
- Authors
- Naci, H., Brugts, J. J., Fleurence, R., Tsoi, B., Toor, H., & Ades, A.
- Affiliations
- London School of Economics and Political Science (GB)
- Erasmus MC (NL)
- Patient-Centered Outcomes Research Institute (US)
- University of Bristol, Bristol, UK
- Corresponding author
- Naci, Huseyin
- Venue
- European Journal of Preventive Cardiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-02-27
- Volume
- 20
- Issue
- 4
- Pages
- 641-657
- ISSN
- 2047-4873 (ISSN-L)
- 2047-4881
- OpenAlex
- W2132064529
- Cited by
- 202
- References
- 47
- Citations by year
- 2026: 1 · 2025: 11 · 2024: 14 · 2023: 18 · 2022: 5 · 2021: 13 · 2020: 12 · 2019: 17 · 2018: 26 · 2017: 16 · 2016: 19 · 2015: 21 · 2014: 21 · 2013: 8
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- European Journal of Preventive Cardiology (publishedVersion)
- PubMed (publishedVersion)
- London School of Economics and Political Science Research Online (London School of Economics and Political Science) (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- statins, major coronary events, all-cause mortality, primary prevention, secondary prevention, cardiovascular disease, atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, statin comparison, dose-response relationship, cardiovascular risk reduction, lipid-lowering therapy
- MeSH terms
- Coronary Disease, Humans, Primary Prevention, Risk Factors, Odds Ratio, Randomized Controlled Trials as Topic, Treatment Outcome, Controlled Clinical Trials as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Evidence-Based Medicine, Dyslipidemias, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.